Elucidating whether myelin dysfunction can trigger Aβ and p-tau pathology as an upstream event in AD pathogenesis would provide strong rationale for therapeutic development targeting myelin pathology at early stages of the disease (Bartzokis, 2011). The gene discussed is MAPT; the disease is Alzheimer disease.